Curtana Pharmaceuticals

12 articles about Curtana Pharmaceuticals

• Abstract Published in Neuro-Oncology Demonstrates Curtana Pharmaceuticals’ CT-179 Prolonged Event-free Survival in an Animal Model of Medulloblastoma

  6/16/2021

  Data Presented in Oral Presentation at the SNO 6th Biennial Pediatric Neuro-Oncology Research Conference.

• Curtana Pharmaceuticals’ CT-179 Receives Rare Pediatric Disease Designation from the U.S. FDA for the Treatment of Medulloblastoma

  10/6/2020

  Curtana Pharmaceuticals, a privately-held, preclinical stage biopharmaceutical company, today announced that the Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation to CT-179, the company’s lead Olig2 inhibitor, for the treatment of medulloblastoma (MB).

• Curtana Pharmaceuticals Successfully Completes Pre-IND Submission For CT-179 For The Treatment Of Malignant Gliomas

  8/22/2017

• Halloran Consulting Group Announces Role As U.S. Regulatory Lead For Curtana Pharmaceuticals’ CT-179 Orphan Drug Designation For The Treatment Of Gliomas

  8/16/2017

• Curtana Pharmaceuticals Granted FDA Orphan Drug Designation For CT-179 For The Treatment Of Gliomas

  8/15/2017

• angelMD Invests In Brain Cancer Treatment Innovator Curtana Pharmaceuticals

  2/9/2017

• Curtana Pharmaceuticals Selected To Present At Inaugural University Startups Demo Day In Washington, DC

  9/7/2016

• Curtana Pharmaceuticals Receives Top Honors At The 5th Annual Texas Life Science Forum

  6/1/2016

• Gary W. Pace Joins Curtana Pharmaceuticals Board Of Directors

  11/18/2015

• Martin Simonetti Joins Curtana Pharmaceuticals Board Of Directors

  9/1/2015

• Curtana Pharmaceuticals Awarded National Institutes of Health (NIH) Small Business Technology Transfer Grant To Advance Glioblastoma Cancer Therapy

  10/1/2014

• Curtana Pharmaceuticals Awarded $7.6 Million Grant From The Cancer Prevention And Research Institute Of Texas

  8/21/2014